The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies

Affiliations

• ¹ Department of Gynecology Oncology, The Tumor Hospital, Harbin Medical University, Harbin, P.R. China.
• ² Department of Gynecology Oncology, The Tumor Hospital, Harbin Medical University, Harbin, P.R. China. louge@ems.hrbmu.edu.cn.
• ³ Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou, P.R. China. ldyy_jinwl@lzu.edu.cn.